­
­
­
­

Inventi Rapid - Molecular Pharmacology

Patent Watch

  • G-proteins

    G.sub..alpha.q-Gustducin chimeric G-proteins that functionally couple to G-protein coupled receptors. The chimeras can be expressed in heterologous cell systems and can be used as the basis of assays for identifying modulators of taste response, in particular bitter, sweet or umami taste responses.

  • Methylene blue-curcumin analog for the treatment of Alzheimer's Disease

    A methylene blue-curcumin hybrid useful in treating Alzheimer's Disease.

  • Method for manufacturing a recombinant polyclonal protein

    The invention relates to a method for manufacturing a recombinant polyclonal protein composition, in particular a recombinant polyclonal antibody composition. The method comprises obtaining a collection of cells transfected with a collection of variant nucleic acid sequences, wherein each cell in the collection is transfected with and capable of expressing one member of the collection, which encodes a distinct member of a polyclonal protein. The cells are cultured under suitable conditions for expression of the polyclonal protein, which is obtained from the cells or culture supernatant. The nucleic acid sequence is introduced into the cells by transfection with a collection of vectors. The present method is suitable for manufacturing recombinant polyclonal antibodies for therapeutic uses.

  • Use of a polyphenol for the treatment of a cancerous or precancerous lesion of the skin

    A method for treating cancerous or pre-cancerous lesions of the skin by administering a pharmaceutically effective amount of a polyphenol to a patient as well as to the production of a medicament thereto is described herein.

  • Kinase inhibitors

    The present invention provides a method for identifying inhibitors of protein kinases. Methods are also provided for inhibiting protein kinase activity. Specific non-peptide protein tyrosine kinase inhibitors are provided. The protein kinases produced using the method of the present invention may be used to treat a number of conditions in patients, including cancer, psoriasis, atherosclerosis, or immune system activity.

  • Recombinant antibodies for treatment of respiratory syncytial virus infections

    Disclosed are novel polyclonal antibodies, which target respiratory syncytial virus (RSV), as well as novel high affinity antibody molecules reactive with RSV. The polyclonal antibodies may comprise antibody molecules which are reactive with both RSV protein F and RSV protein G, and preferably the polyclonal antibodies target a variety of epitopes on these proteins. The antibody molecules of the invention have shown superior efficacy in vitro and/or in vivo. Also disclosed are methods of producing the antibodies of the invention as well as methods of their use in treatment or prevention of RSV infection.

  • c-MET protein kinase inhibitors

    The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders. ##STR00001##

  • Isethionate salt of a selective CDK4 inhibitor

    Disclosed are polymorphs of the isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H- -pyrido[2,3-d]pyrimidin-7-one, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.

  • Genes and markers in type 2 diabetes and obesity

    Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed.

  • Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof

    The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease and in particular VT and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

  • Methods for the identification of modulators of OSGPR114 or OSGPR78 activity, and their use in the treatment of disease

    This invention relates to the identification of LPA as a ligand for the G-protein coupled receptors OSGPR114 and OSGPR78. The invention is directed to new methods for screening candidate drugs for their ability to modulate the activity of OSGPR114 or OSGPR78, and new pharmaceutical agents identified by these methods. It is also directed to the use of such agents in the manufacture of medicaments for the treatment of OSGPR114 or OSGPR78 mediated diseases, and methods of treating diseases such as cancers by administering to an individual a therapeutic amount of a modulator of OSGPR114 or OSGPR78 identified by these methods.

  • Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods

    This invention is directed to indolone derivatives which are antagonists or the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.

  • Use and administration of bacterial efflux pump inhibitors

    This invention provides for efflux pump inhibitors to be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens, novel efflux pump inhibitors, combined dosage forms of efflux pump inhibitors with an antimicrobial, and novel medical methods.

  • Method for determining the specific growth rate of a distinct cell population within a non-homogeneous system

    The present invention provides a method for measuring the specific rate of ribosome synthesis for a distinct cell population, such as a distinct microbial population. For an actively growing (or non-growing) culture, the specific rate of ribosome synthesis is identical to the specific growth rate of the culture. With the method of the invention, researchers will be able to measure the specific growth rate of distinct cell populations in mixed cultures, such as biological reactor systems or environmental samples. In addition, the method of the invention provides the ability to identify members of a distinct cell population that are rapidly growing.

  • Peptides for the treatment of cancer associated with the human papilloma virus (HPV) and other epithelial tumors

    This invention is related to the Molecular Pharmacology field and especially to the development of peptides useful for treating epithelial tumors and mainly those associated to oncogenic types of HPVs. The main objective of this invention is to identify peptides whose structure permits to block the Casein Kinase II (CKII) phosphorylation domain by direct interaction with such a site. In the present invention it is shown eleven cyclic peptides with different aminoacid sequences which inhibit the CKII phosphorylation in vitro, exhibit cytotoxicity on HPV-16 transformed cells (CaSki) and also increase the sensitivity of these cells to the cytostatic effect of interferon (IFN). Furthermore, the invention relates to the use of these peptides conjugated or fused to other peptides and chemical compounds which penetrates into cells as well as with the use of both peptide and chemical mimetic molecules.

  • Methods and systems for drug screening and computational modeling based on biologically realistic neurons

    A method for screening a test composition for potential efficacy in treatment of a disorder includes a first computer model representative of a volume of disease-afflicted neural tissue comprising biologically realistic neurons exposed to the test composition; and providing an initial excitation to the first computer model. Following a selected computation interval, a first outcome is determined. The first outcome indicates a response of the first computer model to the initial excitation and indicates whether the test composition has the potential to be effective in treating the disorder.

  • Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof

    The present invention relates to polynucleotides encoding immunogenic HIV type C Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of Gag- and/or Env-containing proteins are also described.

  • APO E analogs and methods for their use

    Novel ApoE-protein transduction domain conjugates are disclosed which are useful for treating disorders including CNS inflammation, traumatic brain injury, cerebral ischema, Alzheimer's Disease and other brain disorders.

  • Potent LNA oligonucleotides for the inhibition of HIF-1a expression

    The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5'-(T.sub.x)G.sub.xG.sub.xc.sub.sa.sub.sa.sub.sg.sub.sc.sub.sa.sub.st.sub- .sc.sub.sc.sub.sT.sub.xG.sub.xT-3' and 5'-(G.sub.x)T.sub.xT.sub.xa.sub.sc.sub.st.sub.sg.sub.sc.sub.sc.sub.st.sub- .st.sub.sc.sub.sT.sub.xT.sub.xA-3', wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript "s" designates a phosphorothioate link between neighbouring nucleotides/LNA nucleotide analogues, and subscript "x" designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/LNA nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g. diabetic retinopathy, macular degeneration (ARMD), psoriasis, rheumatoid arthritis and other inflammatory diseases.

  • Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use

    Some exemplary embodiments comprise fluoro-containing derivatives of pyrido[4,3-b]indoles (and exemplary methods of making the same) that may be administered to a mammal (including a human) in an effective amount for potential use in the treatment or prophylaxis of neurological disorders including AD, mild cognitive impairment, senile and vascular dementia, HD, ALS, Parkinson's disease, AIDS-related dementia, ischaemic cerebral pathologies, neuropathic pain, ADHD (attention deficit disorder/hyperactivity syndrome), eating disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia (in particular the cognitive deficit of schizophrenia), stroke and also disorders associated with spinal trauma and/or head injury. These derivatives may also be useful for the treatment of borderline personality disorder, obesity, and for use as geroprotectors. The compounds may also be used as "pharmacological tools" for an investigation of the mechanism of protection against neurodegeneration disorders in vivo or in vitro.

  • Receptor(SSTR2)-selective somatostatin antagonists

    SRIF peptide antagonists, which are selective for SSTR2 in contrast to the other cloned SRIF receptors and which bind with high affinity to the cloned human receptor SSTR2 but do not activate the receptor, have many useful functions. Because they do not bind with significant affinity to SSTR1, SSTR3, SSTR4 or SSTR5, their administration avoids potential undesirable side effects. Because they block the receptor function, they can be used therapeutically to block certain physiological effects which SSTR2 mediates. By incorporating radioiodine or the like in these SSTR2-selective SRIF antagonists, a labeled compound useful in drug-screening methods is provided. Alternatively, for use in therapy, highly radioactive moieties can be N-terminally coupled, complexed or chelated thereto.

  • Methods for Purifying Cells Derived from Pluripotent Stem Cells

    The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention provides methods of characterization of cells differentiated into cells expressing markers characteristic of the pancreatic endocrine lineage utilizing unique surface markers. The present invention also provides methods to enrich or sort cells expressing markers characteristic of the pancreatic endocrine lineage. The present invention also provides methods to deplete cells that may contaminate populations of cells expressing markers characteristic of the pancreatic endocrine lineage formed by the methods of the present invention, thereby reducing the incidence of tumor formation in vivo following transplantation.

  • Dynamic visualization of expressed gene networks in living cells

    The present invention provides functional annotation of novel genes by detection of interactions of their encoded proteins with known proteins followed by assays to validate that the gene participates in a specific cellular function. The instant invention also provides an experimental strategy that allows for detection of protein interactions and functional assays with a single reporter system. Interactions among network component proteins are detected and probed with stimulators and inhibitors of the network and subcellular location of the interacting proteins is determined. Additionally, applicants' use this strategy to map a signal transduction network that controls the G.sub.0 to G.sub.1 transition in eukaryotes. Analysis of 148 combinations of 65 protein pairs in mammalian cells allows applicants' to propose a model of network architecture. The results demonstrate the feasibility of employing this strategy in genome-wide functional annotation efforts.

  • METHODS OF TREATING THROMBOEMBOLIC DISORDERS

    The field of the invention relates to methods for dissolving a thrombus using inhibitors of platelet contractility. More particularly, the present invention relates to the use of an inhibitor of platelet contractility in combination with one or more thrombolytic agents and optionally one or more anticoagulants for inhibiting platelet contraction and consolidation in the developing thrombus.

  • G PROTEIN COUPLED RECEPTORS AND USES THEREOF

    The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels.

  • POTENT LNA OLIGONUCLEOTIDES FOR THE INHIBITION OF HIF-1A EXPRESSION

    The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5'-(T.sub.x)G.sub.xG.sub.xc.sub.sa.sub.sa.sub.sg.sub.sc.sub.sa.sub.st.sub- .sc.sub.sc.sub.sT.sub.xG.sub.xT-3' and 5'-(G.sub.x)T.sub.xa.sub.sc.sub.st.sub.sg.sub.sc.sub.sc.sub.st.sub.st.sub- .sc.sub.sT.sub.xT.sub.xA-3', wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript "s" designates a phosphorothioate link between neighbouring nucleotides/LNA nucleotide analogues, and subscript "x" designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/LNA nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g. diabetic retinopathy, macular degeneration (ARMD), psoriasis, rheumatoid arthritis and other inflammatory diseases.

  • PEPTIDES THAT ENHANCE ACETYLCHOLINESTERASE EXPRESSION

    The present invention provides novel chimeric peptides and novel methods for treating animals including humans by administering the novel chimeric peptides. In particular, the invention is useful for enhancing endogenous acetylcholinesterase expression in individuals exposed to organophosphate compounds, such as nerve gases and pesticides.

  • DIFFERENTIAL GENE EXPRESSION IN PHYSIOLOGICAL AND PATHOLOGICAL ANGIOGENESIS

    Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIII.alpha.1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed.

  • Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism

    Compositions and methods for the detection and treatment of autism and autistic spectrum disorder are provided.

  • GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS

    Disclosed herein is a driver gene signature for predicting survival in patients with solid tumors, such as hepatocellular carcinoma (HCC) and breast cancer. The gene signature includes ten tumor-associated genes, SH2D4A, CCDC25, ELP3, DLC1, PROSC, SORBS3, HNRPD, PAQR3, PHF17 and DCK. A decrease in DNA copy number or mRNA expression of SH2D4A, CCDC25, ELP3, DLC1, PROSC and SORBS3 in solid tumors is associated with a poor prognosis, while a decrease in DNA copy number or mRNA expression of HNRPD, PAQR3, PHF17 and DCK in solid tumors is associated with a good prognosis. Thus, provided herein is a method of predicting the prognosis of a patient diagnosed with HCC or breast cancer by detecting expression of one of more tumor-associated genes in a tumor sample and comparing expression of the one or more tumor-associated genes in the tumor sample to a control. Also provided is a method of treating a patient diagnosed with HCC or breast cancer by administering a therapeutically effective amount of an agent that alters expression or activity of one or more of the disclosed tumor-associated genes. Further provided are arrays comprising probes or antibodies specific for a plurality of tumor-associated genes or proteins.

  • Compositions And Methods For Inhibiting Expression Of A Gene From The Ebola Virus

    The invention relates to a double-stranded ribonucleic acid (dsRNA) FOR INHIBITING THE expression of a gene from the Ebola virus.

  • METHOD OF IMMOBILIZING A PROTEIN OR MOLECULE VIA A MUTANT DEHALOGENASE THAT IS BOUND TO AN IMMOBILIZED DEHALOGENASE SUBSTRATE AND LINKED DIRECTLY OR INDIRECTLY TO THE PROTEIN OR MOLECULE

    A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate and has at least two amino acid substitutions relative to the wild-type hydrolase. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein.

  • METHODS OF MONITORING CONDITIONS BY SEQUENCE ANALYSIS

    The invention is directed to methods of generating sequence profiles of populations of nucleic acids, whose member nucleic acids contain regions of high variability, such as populations of nucleic acids encoding T cell receptors or B cell receptors. In one aspect, the invention provides pluralities of sets of primers for generating nested sets of templates from nucleic acids in such populations, thereby insuring the production of at least one template from which sequence reads are generated, despite such variability, or dispite limited lenghs or quality of sequence reads. In another aspect, members of such populations are bidirectionally sequenced so that further sequence information is obtained by analyzing overlapping sequence reads in the zones of highest variability.

  • Methods of Primer Extension Using Porous Particle Supports

    The invention provides particle compositions having applications in nucleic acid analysis. Nucleic acid polymer particles of the invention allow polynucleotides to be attached throughout their volumes for higher loading capacities than those achievable solely with surface attachment. In one aspect, nucleic acid polymer particles of the invention comprise polyacrylamide particles with uniform size distributions having low coefficients of variations, which result in reduced particle-to-particle variation in analytical assays. Such particle compositions are used in various amplification reactions to make amplicon libraries from nucleic acid fragment libraries.

  • HYPOALLERGENIC MOLECULES

    The present invention relates to a hypoallergenic molecule consisting of Bet v Ia or an allergen having at least 40% identity to Bet v Ia comprising mutations of at least four amino acid residues in the region of amino acids 100 to 125 of Bet v Ia or its corresponding region of the allergen having at least 40% identity to Bet v Ia.

  • MINICELLS EXPRESSING ANTIBODIES OR DERIVATIVES THEREOF AND COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS

    Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell.

  • METHODS AND KITS FOR ANALYZING POLYNUCLEOTIDE SEQUENCES

    The present invention features methods for analyzing a sequence of a target polynucleotide by detecting incorporation of a nucleotide into its complementary strand, where the polynucleotides may be bound at high density and at single molecule resolution. The invention also features labeling moieties and blocking moieties, which facilitate chain termination or choking. Certain aspects provide for temporal detection of the incorporations; some allow for asynchronous analysis of a plurality of target polynucleotides and the use of short sequencing cycles. Surface chemistry aspects of the sequencing methods are also provided. The method may also be used in kits, said kits designed to carry out and facilitate the methods provided herein.

  • METHODS AND COMPOSITIONS FOR DETECTING THE ACTIVATION STATE OF MULTIPLE PROTEINS IN SINGLE CELLS

    The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.

  • SOMATOSTATIN ANALOGS WITH INHIBITORY ACTIVITY TO GROWTH HORMONE RELEASE

    Provided are therapeutic and diagnostic somatostatin analogs including radiotherapeutic and radiodiagnostic reagents, and methods of making and use thereof.

  • MUTATED EIF4E SEQUENCES FROM POTATO WHICH ARE USEFUL IN IMPARTING VIRUS RESISTANCE

    A nucleic acid molecule encoding a mutant form of wild-type translation initiation factor elF4E is disclosed A mutation comprising one or more of I70N, I70E, L82R, DI12N, L48F, S68K, A77D or MI09I in SEQ ID NO 1 imparts virus resistance to potato Nucleic acid constructs, expression vectors, cells, plants, and plant seeds containing the nucleic acid sequence are also disclosed, as are methods of imparting virus resistance to plants.

  • MODIFIED CRY3A TOXINS AND NUCLEIC ACID SEQUENCES CODING THEREFOR

    Methods for making a modified Cry3A toxin are disclosed. Such methods include the insertion of a protease recognition site that is recognized by a gut protease of a target insect, such as corn rootworm, into at least one position of a Cry3A toxin so that a modified Cry3A toxin is thus designed. The coding sequence of the modified Cry3A toxin may be transformed into a host cell and the host cell grown under conditions that allow the host cell to produce the modified Cry3A toxin. The host cell may be a plant cell and the plant may be comprised in a transgenic plant. Thus, the transgenic plant may be used to produce the modified Cry3A toxin.

  • COMPOSITIONS AND METHODS FOR THE MODIFICATION OF GENE EXPRESSION

    Novel isolated plant polynucleotide promoter sequences are provided, together with genetic constructs comprising such polynucleotides. Methods for using such constructs in modulating the transcription of DNA sequences of interest are also disclosed, together with transgenic plants comprising such constructs.

  • EXPRESSION CASSETTES FOR TRANSGENIC EXPRESSION OF NUCLEIC ACIDS

    The invention relates to expression cassettes and vectors which contain constitutive promoters of plants and to the use of these expression cassettes or vectors for transgenic expression of nucleic acid sequences, preferably selection markers, in organisms, preferably in plants. The invention further relates to transgenic plants which have been transformed with the expression cassettes or vectors, to cultures, parts or propagation material derived from these plants, and to the use of these plants for the production of food and animal feedstuffs, seed, pharmaceuticals, or fine chemicals.

  • RNA SEQUENCE-SPECIFIC MEDIATORS OF RNA INTERFERENCE

    The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response. This specific targeting of a particular gene function is useful in functional genomic and therapeutic applications.

  • ANTISENSE MODULATION OF INTERLEUKINS 17 AND 23 SIGNALING

    Provided are antisense oligonucleotides and other agents that target and modulate IL-17 and/or IL-23 signaling activity in a cell, compositions that comprise the same, and methods of use thereof. Also provided are animal models for identifying agents that modulate 17 and/or IL-23 signaling activity.

  • NOVEL CYANOPYRIMIDINE DERIVATIVE

    The present invention relates to a novel cyanopyrimidine compound and a pharmaceutical composition which have a safe and potent adenosine A2a receptor agonistic activity.

  • USE OF CB1 ANTAGONISTS AND/OR INVERSE AGONISTS FOR THE PREPARATION OF DRUGS THAT INCREASE MOTOR NEURON EXCITABILITY

    Use of a CB1 receptor antagonist and/or inverse agonist, preferably rimonabant, for the preparation of drugs useful for increasing motor neuron excitability in the cerebral cortex and/or in the brain stem and/or at the spinal level, as well as a method for increasing motor neuron excitability through the administration of a CB1 antagonist/inverse agonist receptors, and to the use of a pharmaceutical composition which comprises a CB1 receptor antagonist and/or inverse agonist, preferably rimonabant, for increasing motor neuron excitability in the cerebral cortex and/or in the brain stem and/or at the spinal level.

  • METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE

    Small molecules and their derivatives are described for the treatment and/or prevention of intestinal fluid loss. Also disclosed are methods of using said molecules and their derivatives to treat and/or prevent conditions associated with increased levels of 3',5'-adenosine monophosphate. Specific compositions of the invention are also novel.

  • METHODS AND COMPOSITIONS FOR REPROGRAMMING CELLS

    The present invention is directed, in part, to methods and compositions comprising inhibitors of micro RNA-145 and activators of the TGF-.beta. signaling pathway to permit reprogramming using only small molecule compounds. Also described herein are methods to distinguish cancer cells or cells having cancerous potential in human iPS cell populations, based on determining the balance of p21-p53 expression levels, or ratio thereof in reprogrammed cells. In further aspects, methods and compositions to cause redifferentiation of a hepatoma cell to a hepatocye-like cell using acyclic retinoid and inhibitors of AKR1B10 are provided.

  • Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof

    Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

  • CANCER RELATED GENE, LGN/GPSM2

    The present invention provides methods for detecting and diagnosing cancer, which method involves the determination of the expression level of the LGN/GPSM2 gene. Furthermore, the present invention provides methods of screening for therapeutic agents useful in the treatment or prevention of cancer and methods for treating breast cancer. Moreover, the present invention provides siRNAs targeting the LGN/GPSM2 gene, which are useful in the treatment or prevention of cancer.

  • POTENT CHIMERIC NRTI-NNRTI BIFUNCTIONAL INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE

    The present invention relates to compounds, in particular, dual antagonists comprising a nucleoside reverse transcriptase inhibitor (NRTI) or a nucleoside competititive reverse transcriptase inhibitor and a non-nucleoside reverse transcriptase inhibitor (NNRTI), linked together using a chemical linker, which may be used to inhibit HIV (HIV-1) reverse transcriptase and in the treatment of HIV infections, more severe cases of HIV infections, including ARC and AIDS, including reducing the likelihood of these infections and disease states. ##STR00001## ##STR00002## ##STR00003##

  • CD19 BINDING AGENTS AND USES THEREOF

    This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.

  • INHIBITORS OF RECEPTOR TYROSINE KINASES AND METHODS OF USE THEREOF

    The present invention provides moieties that bind to an Ig-like domain, e.g., D4 or D5, of a human receptor tyrosine kinase, e.g., the human Kit RTK or the PDGFR RTK, or the D7 domain of a type V receptor tyrosine kinase wherein the moieties lock the ectodomain of the receptor tyrosine kinase in an inactive state thereby antagonizing the activity of the receptor tyrosine kinase.

  • 3-AZABICYCLO[3.1.0]HEXYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

    The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors--subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved. ##STR00001##

  • APOE ANALOGS AND METHODS FOR THEIR USE

    Novel ApoE peptide derivatives and ApoE-protein transduction domain conjugates are disclosed which are useful for treating disorders including CNS inflammation, traumatic brain injury, inflammatory bowel disease (also known as Crohn's Disease or ulcerative colitis), cerebral ischemia, atherosclerosis, sepsis, multiple sclerosis and arthritic diseases, Alzheimer's Disease and other brain disorders. The invention encompasses methods for protecting subjects having undergone irradiation or radiotherapy by administration of ApoE or at least one ApoE mimetic peptide.

  • METHODS AND SYSTEMS FOR DRUG SCREENING AND COMPUTATIONAL MODELING BASED ON BIOLOGICALLY REALISTIC NEURONS

    A method for screening a test composition for potential efficacy in treatment of a disorder includes a first computer model representative of a volume of disease-afflicted neural tissue comprising biologically realistic neurons exposed to the test composition; and providing an initial excitation to the first computer model. Following a selected computation interval, a first outcome is determined. The first outcome indicates a response of the first computer model to the initial excitation and indicates whether the test composition has the potential to be effective in treating the disorder.

  • METHOD OF PREPARING ADENOSINE-RESISTANT ANTI-TUMOR T LYMPHOCYTES FOR ADOPTIVE IMMUNOTHERAPY

    In the past, adoptive immunotherapy often failed because the transferred immune cells were inactive in vivo. This disclosure provides a method of producing immune cells that are highly active in vivo. The immune cells may be expanded in vitro in the presence of an adenosine receptor agonist or an antisense nucleic acid that downregulates expression of an adenosine receptor, for example. The immune cells may be tumor-infiltrating lymphocytes (TIL), cytotoxic T lymphocytes (CTL), natural killer (NK) cells, or lymphokine-activated killer (LAK) cells, for example. The methods described herein may be used to treat a number of diseases including cancer, infectious diseases, and immunodeficiencies.

  • Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists

    The invention relates generally to methods of treating and/or preventing proliferative diseases, such as cancers, using antagonists of IL-17. The invention also relates to methods and kits for identifying subjects who are likely to respond to treatment and/or prevention of proliferative diseases with antagonists of IL-17.

  • SGC STIMULATORS OR SGC ACTIVATORS IN COMBINATION WITH PDE5 INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION

    The present invention relates to soluble guanylate cyclase (sGC) and to phosphodiesterases (PDEs) and the pharmacology of sGC stimulators, sGC activators and PDE inhibitors. More particularly, the invention relates to the use of sGC stimulators and sGC activators in combination with PDE5 inhibitors for preparation of medicaments for the treatment of male erectile dysfunction (MED) in particular for the MED treatment of difficult to treat patients and patients not or not fully responding to PDE5 inhibitors.

  • METHODS AND COMPOSITIONS FOR TREATING DIABETES

    The instant invention provides a method of treating an animal suffering a disease characterized by excessive apoptosis by administering a therapeutically effective amount of at least one serine protease inhibitor and thereafter monitoring a decrease in apoptosis. The inhibitor of the invention includes .alpha..sub.1-antitrypsin or an .alpha..sub.1-antitrypsin-like agent, including, but not limited to oxidation-resistant variants of .alpha..sub.1-antitrypsin, and peptoids with antitrypsin activity. The diseases treatable by the invention include cancer, autoimmune disease, sepsis neurodegenerative disease, myocardial infarction, stroke, ischemia-reperfusion injury, toxin induced liver injury and AIDS. The method of the invention is also suitable for the prevention or amelioration of diseases characterized by excessive apoptosis.

  • SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE

    Disclosed are methods for identifying individuals suffering from a CNS disorder (including Alzheimer's Disease, ALS, behavioral disorders, and the like) that could be treated with a CNS drug with greater therapeutic efficacy and lower side effects and the compounds useful for such treatment. Also disclosed are methods for predicting the efficacy of a drug candidate for the treatment of a CNS disorder. The technology is also applicable to drug discovery for evaluation in animal models of neurodegenerative diseases.

  • INDOLINE SCAFFOLD SHP-2 INHIBITORS AND METHOD OF TREATING CANCER

    Protein tyrosine phosphatase (PTP) Shp2 is a non-receptor PTP that involved in cell signaling and regulation of cell proliferation, differentiation, and migration. Shp2 mediates activation of kinases that are involved in the pathogenesis of human carcinoma. A high throughput screen identified compounds that inhibit the PTP Shp2. Several compounds were identified that selectively inhibit Shp2 over Shp1 with low to sub-micromolar activity. Also disclosed are methods of inhibiting a protein tyrosine phosphatase in a cell and treating cancer through selective inhibition of Shp2.

  • COMPOSITIONS AND METHODS FOR TREATMENT OF TAUPATHY

    Provided are electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient for treating an inflammatory neurodegenerative condition or disease (e.g., a taupathy) or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for modulating phosphorylation of tau protein. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membrane potential and/or conductance, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids and therapeutic compositions.

  • MEANS AND METHODS FOR MEDIATING PROTEIN INTERFERENCE

    The present invention belongs to the field of functional proteomics and more particularly to the field of protein aggregation. The invention discloses a method for interfering with the function of a target protein and uses a non-naturally, user-designed molecule, designated as interferor, that has a specificity for a target protein and which induces aggregation upon contact with said target protein. The present invention also discloses such interferor molecules and their use in agrobiotech applications.

  • Proteasome Inhibitors and Methods of Using the Same

    The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.

  • TFPI INHIBITORS AND METHODS OF USE

    The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.

  • Compositions For The Treatment of Central Nervous System Disorders Including Depression Employing Novel Drug Combination Therapy To Reduce Suicidality In Patients

    Described herein are novel methods and formulations for reducing suicidality in human subjects. Such formulations and methods are a combination of lithium and one or more other CNS therapeutic agents such as anti-depressant, mood-stabilizing, anxiolytic, anticonvulsant, antipsychotic, anti-addictive, and appetite suppressant drugs

  • Pharmacologically-active vanilloid carbamates

    This application relates to pharmacologically-active vanilloid compounds which are useful for the treatment of various anti-inflammatory states characterized by inhibition of FAAH, such as, Alzheimer's dementia, Parkinson's disease, depression, pain, rheumatoid arthritis, pathophysiology of mood disorders, multiple sclerosis, and inflammation, or antagonism of TRPV1, such as, for example, Huntington's disease, hypertension, arthritis, allergic airway inflammation, Crohn's disease, ulcerative colitis, and neuropathic pain.

  • USE OF MOMETASONE FUROATE FOR TREATING AIRWAY PASSAGE AND LUNG DISEASE

    The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.

  • DIAGNOSTIC AGENT FOR ISCHEMIC HEART DISEASE RISK GROUP

    The present invention relates to a diagnostic agent for an ischemic heart disease risk group comprising an anti-brain-derived neurotrophic factor antibody as an effective ingredient, to an assay method for an ischemic heart disease risk group performed by measuring a brain-derived neurotrophic factor concentration in blood, and to a suppressive/preventive drug for ischemic heart disease, particularly for post-infarction myocardial remodeling, comprising a brain-derived neurotrophic factor.

  • NOVEL COMPOSITIONS AND METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF HUMAN CANCERS

    The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of "sensitivity markers." These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of "resistance markers." These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.

  • METHODS FOR TREATING BRAIN TUMORS

    Methods for treating brain tumors involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatment.

  • METHODS FOR EVALUATING GASTROINTESTINAL ABSORPTION OF CHEMICALS

    Nucleic acids and vectors for interfering with the expression of membrane efflux transport proteins in cells that express such proteins are provided. Also provided are cells and cell lines comprising such nucleic acids and vectors. Methods for screening chemicals and biomolecules for gastrointestinal absorption in animals, and kits for practicing such methods are also provided.

  • METHODS AND KITS TO PREDICT THERAPEUTIC OUTCOME OF TYROSINE KINASE INHIBITORS

    Methods of using specific microRNA to identify subjects with non-small cell lung cancer likely or unlikely to respond to treatment with tyrosine kinase inhibitors such as erlotinib, sunitinib, or vandetanib; methods of treating subjects based on identification of said subjects as likely to respond to treatment with tyrosine kinase inhibitors; and kits that facilitate the performance of the methods are disclosed.

  • NOVEL GENES, COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CERVICAL CANCER

    The invention relates to newly discovered nucleic acid molecules and proteins associated with cervical cancer including pre-malignant conditions such as dysplasia. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers are provided.

  • Molecular Markers and Assay Methods for Characterizing Cells

    Disclosed herein are molecular markers and assay methods for characterizing cells. As disclosed, the methods entail determining a methylation state of at least one CpG in a region of a nucleotide molecule of the cell, comparing the methylation state with that of a corresponding CpG of a comparison cell of a known cell type, a known cell line, or a known cell strain, and distinguishing, identifying or designating the cell type, the cell line or the cell strain of the cell based on whether the methylation state is the same or different from that of the corresponding CpG.

  • MOLECULAR CONJUGATES COMPRISING HUMAN MONOCLONAL ANTIBODIES TO DENDRITIC CELLS

    Isolated human monoclonal antibodies and antigen-binding portions thereof which specifically bind to dendritic cells are disclosed. Also disclosed are bispecifics, immunotoxins and antigen conjugates which include the antibodies or antibody portions. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

  • METHODS AND DEVICES OF SEPARATING MOLECULAR ANALYTES

    A method of separating a mixture of a plurality of molecular analytes having different isoelectric points (pIs). The method comprises placing a solution containing a mixture of a plurality of molecular analytes in a separation volume, generating a pH profile having a plurality of pH zones across an axis of the separation volume, and adjusting a profile of the pH profile to induce a migration of a first molecular analyte along the axis apart from a second molecular analyte. The first and second molecular analytes having different pIs.

  • Composition With Preventive or Improvement Effect on Symptoms or Diseases Associated with Stress-Induced Behavior Disorders

    A composition with a preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders, comprising arachidonic acid and/or a compound comprising arachidonic acid as a constituent fatty acid.

  • METHODS OF TREATING DISEASES

    The present invention relates to computer-implemented methods and system for analysing a biomarker which cycles in a subject. In some other aspects, the present invention relates to analysing a biomarker which at least initially increases or decreases in amount in a subject following a treatment for a disease. In further aspects, the present invention relates to computer-implemented methods and systems for determining a preferred time to administer a therapy to treat a disease in a subject. The present invention also relates to computer program product to implement the methods. Further, the present invention relates to methods of determining the timing of treating a disease in a subject in which the immune system is cycling.

  • PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED INFLAMMATORY DISEASES

    The present invention relates to a pharmaceutical composition comprising a combination of 1-benzyl-3-hydroxymethyl-indazole derivative, a pressure lowering agent selected from ACE-inhibitors, renin inhibitors, ARBs and CCBs, and/or a cholesterol lowering agent selected from statin derivatives. The combination showed an additive and synergistic activity in reducing MCP-1 levels, thus significantly improving inflammatory response inhibition and consequently reducing complications occurring in patients suffering from inflammatory diseases.

  • Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases

    The preset invention relates to combination pharmaceutical composition comprising an activated-potentiated from of an antibody to gamma interferon, and an activated-potentiated form of an antibody to S-100 protein and method of treating multiple sclerosis and other neurodegenerative diseases, as well as the diseases and conditions associated with neuroinfections.

  • (3-FLUORO-2-HYDROXY)PROPYL-FUNCTIONALIZED ARYL DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR THE DIAGNOSIS OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASES

    The present invention relates to (3-fluoro-2-hydroxy)propyl-functionalized aryl derivatives or to the pharmaceutically acceptable salt thereof, to a method for preparing same, and to a pharmaceutical composition containing same as active ingredients for the diagnosis or treatment of neurodegenerative brain diseases. The aryl derivatives of the present invention are (3-fluoro-2-hydroxy)propyl-functionalized to increase the polarity thereof, and therefore the drugs containing the aryl derivatives can easily permeate into the cerebrovascular membrane, thus increasing the effectiveness of the drugs. As the aryl derivatives of the present invention strongly bind to .beta.-amyloid, the aryl derivatives, when labeled with radioisotope, can be used as a diagnostic agent for non-invasively diagnosing early Alzheimer's disease. Further, the aryl derivatives of the present invention bind to low molecular .beta.-amyloid peptide conjugates to inhibit the generation of malignant high molecular .beta.-amyloid plaque, and thus can be effectively used as a therapeutic agent for neurodegenerative brain diseases such as Alzheimer's disease.

  • COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES

    The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.

  • METHODS FOR TREATING DISEASES OF THE RETINA

    Disclosed herein is a method of treating disorders of the retina comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of Formula I ##STR00001## as defined herein. These compounds are useful as PDE10 inhibitors.

  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

    Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

  • COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASES

    Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.

  • THERAPEUTIC AGENT AND THERAPEUTIC METHOD FOR PERIODONTAL DISEASES AND PULPAL DISEASES

    The objects of the present invention are: to provide a therapeutic agent and a therapeutic method for periodontal diseases and pulpal diseases, a transplant for periodontal tissue regeneration, and a method for regenerating the periodontal tissue. According to the present invention, there are provided therapeutic agents for periodontal diseases and pulpal diseases which comprise neurotrophic factors as an active ingredient.

  • CARBONIC ANHYDRASE I SERVING AS NOVEL ANTIGEN TO BE USED FOR TREATMENT OF AUTOIMMUNE DISEASES

    The purpose of the present invention is to provide a method for treating autoimmune diseases. Disclosed is a method or the like for the treatment of autoimmune diseases, which utilizes an antigen-specific tolerogenic antigen presenting cell. Specifically disclosed are: a method for producing an antigen-specific tolerogenic antigen presenting cell, which is characterized by using carbonic anhydrase I; an immunogenic antigen presenting cell which is specific to carbonic anhydrase I; and a method or the like for the treatment of autoimmune diseases (especially inflammatory bowel diseases), which is characterized by using a tolerogenic antigen presenting cell which is specific to carbonic anhydrase I.

  • ANTI-NOTCH3 AGONIST ANTIBODIES AND THEIR USE IN THE TREATMENT OF NOTCH3-RELATED DISEASES

    The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.

  • TREATMENT OF RENAL DISEASES

    Compositions for the treatment of renal diseases and disorders utilize agents which inhibit alphaV integrin molecules in vivo. Methods of treatment include use of these agents in the prevention and treatment of proteinuria, progressive glomerular disease and glomerular disease amongst others.

  • Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases

    The present invention relates to a pharmaceutical composition useful for treating or preventing inflammatory disease and cell damage, and a method for treating or preventing inflammatory disease and cell damage. The present invention uses the 2-hydroxybenzoic acid derivative represented by the specific chemical formula or its pharmaceutically acceptable salt. The compound of the present invention is useful for treating or preventing cell damage and inflammatory disease including gastritis, gastric ulcer, pancreatitis, colitis, arthritis, diabetes, arteriosclerosis, nephritis, hepatitis, Alzheimer's disease, Parkinson's disease and Lou Gehrig's disease.

  • GENOME EDITING OF GENES INVOLVED IN ADME AND TOXICOLOGY IN ANIMALS

    The present invention provides genetically modified animals and cells comprising edited chromosomal sequences involved in ADME and toxicology. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. The invention also provides zinc finger nucleases that target chromosomal sequence involved in ADME and toxicology and the nucleic acids encoding said zinc finger nucleases. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences involved in ADME and toxicology.

  • ULTRASOUND NEUROMODULATION FOR TREATMENT OF AUTISM SPECTRUM DISORDER AND ALZHEIMERS DISEASE AND OTHER DEMENTIAS

    Disclosed are methods and systems and methods for non-invasive neuromodulation using ultrasound for the Treatment of Autism Spectrum Disorders and Alzheimer's Disease and other dementias. The neuromodulation can produce acute or long-term effects. The latter occur through Long-Term Depression (LTD) and Long-Term Potentiation (LTP) via training. Included is control of direction of the energy emission, intensity, frequency, pulse duration, firing pattern, and phase/intensity relationships to targeting and accomplishing up regulation and/or down regulation.

  • ULTRASOUND NEUROMODULATION FOR TREATMENT OF AUTISM SPECTRUM DISORDER AND ALZHEIMERS DISEASE AND OTHER DEMENTIAS

    Disclosed are methods and systems and methods for non-invasive neuromodulation using ultrasound for the Treatment of Autism Spectrum Disorders and Alzheimer's Disease and other dementias. The neuromodulation can produce acute or long-term effects. The latter occur through Long-Term Depression (LTD) and Long-Term Potentiation (LTP) via training. Included is control of direction of the energy emission, intensity, frequency, pulse duration, firing pattern, and phase/intensity relationships to targeting and accomplishing up regulation and/or down regulation.

  • TREATMENT REGIMEN FOR PARKINSON'S DISEASE

    Provided is an improved treatment for Parkinson's Disease where the efficacy of L-Dopa treatment is increased by including gene therapy in the treatment regimen. The combination therapy results in long-term improvements in response to L-Dopa and diminished side effects caused by L-Dopa.

  • NITROXIDE THERAPY FOR THE TREATMENT OF VON HIPPEL - LINDAU DISEASE (VHL) AND RENAL CLEAR CELL CARCINOMA (RCC)

    The invention provides therapeutic methods that include administering a stable nitroxide to a subject that has, is suspected to have, or is at risk for having a condition associated with reduced VHL or elevated HIF-2.alpha.

  • TREATMENT OF COPD, GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD), FOOD ALLERGIES AND OTHER GASTROINTESTINAL CONDITIONS AND DISORDERS AMELIORATED BY PROPER HISTAMINE MANAGEMENT USING A COMBINATION OF HISTIDINE DECARBOXYLASE INHIBATORS, LRA DRUGS, ANTI-H1 AND/OR ANTI-H2 DRUGS

    The invention provides a method for the treatment of COPD and/or gastrointestinal disease conditions ameliorated by histamine management in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor.

  • Chlorite in the Treatment of Neurodegenerative Disease

    The invention features methods of treating a macrophage-associated neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), or multiple sclerosis (MS) in a subject by administering chlorite in an amount effective to decrease blood immune cell activation. The invention also features methods of monitoring therapy by assessing blood immune cell activation before and after therapy.

  • NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE

    The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.

  • NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE

    The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.

  • Methods for Treating Fatty Liver Disease

    The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their sequelae by administration of uridine or a compound that modulates one or more uridine phosphorylases in a subject in need thereof.

  • Methods, Systems, and Computer-Readable Media for Disease Management

    Methods, systems, and computer-readable media provide for disease management. According to embodiments, a method for providing social interaction between a first handheld medical testing and monitoring device and a second handheld medical testing and monitoring device is provided. According to the method, at least one of a social networking profile and a diagnostic profile is received from the first handheld medical testing and monitoring device. A second user associated with the second handheld medical testing and monitoring device is selected based on the at least one of the social networking profile and the diagnostic profile. A user list at the first handheld medical testing and monitoring device is populated with a unique identifier enabling communication between a first user associated with the first handheld medical testing and monitoring device and the second user associated with the second handheld medical testing and monitoring device.

  • System and Implantable Device for Treating Chronic Kidney Disease

    An implantable dialysis device with a related medical system for intracorporeal dialysis and ultrafiltration of blood, and methods of use are described. The medical system includes an extracorporeal module, a cutaneous module, and an implantable module. Features of the implantable module facilitate delivery and flow of blood and dialysate through the medical system. A filter pack within the implantable module performs dialysis and ultrafiltration of blood. System cleansing is also described.

  • SYSTEM AND METHOD FOR MINIMALLY INVASIVE DISEASE THERAPY

    A system for treating a lesion site of a patient is disclosed. The system includes a cannula having a lumen, a conduit in communication with said lumen, an introducer stylet removably disposed within said cannula, a resecting device selectively insertable within said cannula, and an adjuvant treatment device selectively insertable within said cannula.

  • PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE

    Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.

  • COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE

    The present invention provides compositions for reducing amyloid plaque burden associated with Alzheimer's disease and methods of using the same.

  • AQUEOUS SOLUTION COMPRISING 3 - QUINUCLIDINONES FOR THE TREATMENT HYPERPROLIFERATIVE, AUTOIMMUNE AND HEART DISEASE

    A liquid composition that is an aqueous solution of a compound of formula (I), wherein the aqueous solution has a pH from about 3.0 to about 5.0. The liquid composition may be used in the treatment of a disorder selected from hyperproliferative diseases, autoimmune diseases and heart diseases.

  • AQUEOUS SOLUTION COMPRISING 3 - QUINUCLIDINONES FOR THE TREATMENT HYPERPROLIFERATIVE, AUTOIMMUNE AND HEART DISEASE

    A liquid composition that is an aqueous solution of a compound of formula (I), wherein the aqueous solution has a pH from about 3.0 to about 5.0. The liquid composition may be used in the treatment of a disorder selected from hyperproliferative diseases, autoimmune diseases and heart diseases.

  • Agonists of Guanylate Cyclase Useful for the Treatment of Hypercholesterolemia, Atherosclerosis, Coronary Heart Disease, Gallstone, Obesity and Other Cardiovascular Diseases

    This invention also provides a method to prevent, control, and treata lipid metabolism disorder, a biliary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.

  • METHODS AND COMPOSITIONS FOR DIAGNOSIS OR PROGNOSIS OF CARDIOVASCULAR DISEASE

    The invention provides methods of screening a mammalian subject to determine if the subject is at risk to develop or is suffering from, cardiovascular disease. In one embodiment, the method comprises detecting a measurable feature of at least two biomarkers in an EMT subfraction, or in a complex containing apoA-I or apoA-III isolated from a biological sample obtained from the subject, wherein the at least two biomarkers are selected from the group consisting of apoA-I, apoA-II, apoB-100, Lp(a), apoC-I, and apoC-III, combinations or portions and/or derivatives thereof, and comparing the measurable features of the at least two biomarkers from the biological sample to a reference standard, wherein a difference in the measurable features of the at least two biomarkers from the biological sample and the reference standard is indicative of the presence or risk of cardiovascular disease in the subject.

  • METHODS AND COMPOSITIONS FOR DIAGNOSIS OR PROGNOSIS OF CARDIOVASCULAR DISEASE

    The invention provides methods of screening a mammalian subject to determine if the subject is at risk to develop or is suffering from, cardiovascular disease. In one embodiment, the method comprises detecting a measurable feature of at least two biomarkers in an EMT subfraction, or in a complex containing apoA-I or apoA-III isolated from a biological sample obtained from the subject, wherein the at least two biomarkers are selected from the group consisting of apoA-I, apoA-II, apoB-100, Lp(a), apoC-I, and apoC-III, combinations or portions and/or derivatives thereof, and comparing the measurable features of the at least two biomarkers from the biological sample to a reference standard, wherein a difference in the measurable features of the at least two biomarkers from the biological sample and the reference standard is indicative of the presence or risk of cardiovascular disease in the subject.

  • ELECTROCHEMICAL METHODS OF DETECTING COLON CANCER CELLS AND USE OF SAME FOR DIAGNOSING AND MONITORING TREATMENT OF THEDISEASE

    A method of detecting cancer cells is disclosed. The method comprises (a) contacting the cell with a substrate for an enzyme under conditions wherein the enzyme catalyzes a reaction of the cell with the substrate, so as to generate a product capable of producing an electrical signal; and (b) measuring a level of the electrical signal, wherein a difference in a level of the electrical signal compared to a predetermined threshold is indicative of a cancer cell. The method may be adapted for diagnosis, monitoring a cancer therapy, identifying agents capable of treating cancer and individually optimizing a cancer therapy.

  • ELECTROCHEMICAL METHODS OF DETECTING COLON CANCER CELLS AND USE OF SAME FOR DIAGNOSING AND MONITORING TREATMENT OF THEDISEASE

    A method of detecting cancer cells is disclosed. The method comprises (a) contacting the cell with a substrate for an enzyme under conditions wherein the enzyme catalyzes a reaction of the cell with the substrate, so as to generate a product capable of producing an electrical signal; and (b) measuring a level of the electrical signal, wherein a difference in a level of the electrical signal compared to a predetermined threshold is indicative of a cancer cell. The method may be adapted for diagnosis, monitoring a cancer therapy, identifying agents capable of treating cancer and individually optimizing a cancer therapy.

  • DIFFERENTIAL GENE EXPRESSION FOR DETECTING AND/OR DIFFERENTIATING LUNG DISEASE

    Disclosed herein are methods, constructs, kits, and the like, which can be used for detecting and/or differentiating interstitial lung disease. For example, idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP) can be detected and/or differentiated using at least one biomarker.

  • DIFFERENTIAL GENE EXPRESSION FOR DETECTING AND/OR DIFFERENTIATING LUNG DISEASE

    Disclosed herein are methods, constructs, kits, and the like, which can be used for detecting and/or differentiating interstitial lung disease. For example, idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP) can be detected and/or differentiated using at least one biomarker.

  • TREATMENT OF HEART DISEASE

    Disclosed herein are methods, compositions and kits for treating cardiac stem cells to be administered to a subject in need thereof, e.g., with a damaged myocardium. The methods, composition and kits of the invention can be used to treat cardiovascular diseases such as heart failure, myocardial infarction and an age-related cardiomyopathy.

  • PEPTIDE WHICH PASSES THROUGH BLOOD-BRAIN BARRIER AND TARGETS APOPTOSIS OF NEURODEGENERATIVE BRAIN DISEASE SITE AND USES THEREOF

    The present invention relates to a peptide that passes through a blood-brain barrier and targets apoptosis of neurodegenerative brain disease-affected sites and uses thereof. More particularly, the present invention relates to a composition for delivering drugs to brain tissues, a composition for detecting apoptotic cells of neurodegenerative brain disease-affected sites, and a composition for imaging the neurodegenerative brain disease-affected sites which comprises a peptide having an amino acid sequence represented by SEQ ID: No. 1 respectively, and a composition for prevention, treatment, or theranosis of neurodegenerative brain diseases comprising said peptide. The peptide of the present invention can be used for detecting apoptosis in neurodegenerative brain diseases and further detecting apoptotic cells (especially apoptotic neuronal cells) in neurodegenerative brain disease-affected sites and imaging, targeted drug delivery, theranosis.

  • GLOBAL DISEASE SURVEILLANCE PLATFORM, AND CORRESPONDING SYSTEM AND METHOD

    A computer-implemented method for identifying and assessing public health events, and a corresponding system and apparatus, includes capturing public health-related information from structured and unstructured sources, where the information is contained in one or more documents, extracting meta-data from the captured public health-related information, creating an index of the extracted meta-data; archiving the meta-data and the documents, where the index links meta-data to its associated document, processing the extracted meta-data according to one or more detection algorithms to determine if an anomaly exists, and where an anomaly exists, providing a public health event notification, and monitoring and evaluating the responses to the public health events.

  • TREATMENT OF HYPERTENSION AND HEART DISEASE VIA SURGERY OF THE STOMACH

    Devices and methods for endolumenally manipulating stomach fundus tissue alter the function of nearby nerves. The altered function of the nerves interacts with the cardiopulmonary system to cause a substantially permanent reduction in blood pressure. The altered nerve function may also treat heart disease as well. This application also relates to devices and methods for endolumenally manipulating stomach tissue to alter hormone production from cells associated with stomach tissue, providing a therapeutic effect in treating hypertension and heart disease, not conventionally associated with the stomach.

  • TREATMENT OF HYPERTENSION AND HEART DISEASE VIA SURGERY OF THE STOMACH

    Devices and methods for endolumenally manipulating stomach fundus tissue alter the function of nearby nerves. The altered function of the nerves interacts with the cardiopulmonary system to cause a substantially permanent reduction in blood pressure. The altered nerve function may also treat heart disease as well. This application also relates to devices and methods for endolumenally manipulating stomach tissue to alter hormone production from cells associated with stomach tissue, providing a therapeutic effect in treating hypertension and heart disease, not conventionally associated with the stomach.

  • Determination of a Measure of a Glycation End-Product or Disease State Using Tissue Fluorescence Lifetime

    The present invention provides methods and apparatuses for determining a measure of a tissue state in an individual. Light emitted by tissue of the individual due to fluorescence of a chemical with the tissue detected. The invention can comprise measuring the fluorescence lifetime in either time-domain or frequency domain modes. The invention can also comprise a variety of models relating fluorescence to a measure of tissue state, for example, multivariate models can be developed that relate lifetime trends of one or more constituents to increasing propensity to diabetes and pre-diabetes. Other biologic information can be used in combination with the fluorescence properties to aid in the determination of a measure of tissue state.

  • ULTRASOUND NEUROMODULATION FOR TREATMENT OF AUTISM SPECTRUM DISORDER AND ALZHEIMERS DISEASE AND OTHER DEMENTIAS

    Disclosed are methods and systems and methods for non-invasive neuromodulation using ultrasound for the Treatment of Autism Spectrum Disorders and Alzheimer's Disease and other dementias. The neuromodulation can produce acute or long-term effects. The latter occur through Long-Term Depression (LTD) and Long-Term Potentiation (LTP) via training. Included is control of direction of the energy emission, intensity, frequency, pulse duration, firing pattern, and phase/intensity relationships to targeting and accomplishing up regulation and/or down regulation.

  • TREATMENT REGIMEN FOR PARKINSON'S DISEASE

    Provided is an improved treatment for Parkinson's Disease where the efficacy of L-Dopa treatment is increased by including gene therapy in the treatment regimen. The combination therapy results in long-term improvements in response to L-Dopa and diminished side effects caused by L-Dopa.

  • TREATMENT REGIMEN FOR PARKINSON'S DISEASE

    Provided is an improved treatment for Parkinson's Disease where the efficacy of L-Dopa treatment is increased by including gene therapy in the treatment regimen. The combination therapy results in long-term improvements in response to L-Dopa and diminished side effects caused by L-Dopa.

  • NITROXIDE THERAPY FOR THE TREATMENT OF VON HIPPEL - LINDAU DISEASE (VHL) AND RENAL CLEAR CELL CARCINOMA (RCC)

    The invention provides therapeutic methods that include administering a stable nitroxide to a subject that has, is suspected to have, or is at risk for having a condition associated with reduced VHL or elevated HIF-2.alpha..

  • TREATMENT OF COPD, GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD), FOOD ALLERGIES AND OTHER GASTROINTESTINAL CONDITIONS AND DISORDERS AMELIORATED BY PROPER HISTAMINE MANAGEMENT USING A COMBINATION OF HISTIDINE DECARBOXYLASE INHIBATORS, LRA DRUGS, ANTI-H1 AND/OR ANTI-H2 DRUGS

    The invention provides a method for the treatment of COPD and/or gastrointestinal disease conditions ameliorated by histamine management in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor.

  • Chlorite in the Treatment of Neurodegenerative Disease

    The invention features methods of treating a macrophage-associated neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), or multiple sclerosis (MS) in a subject by administering chlorite in an amount effective to decrease blood immune cell activation. The invention also features methods of monitoring therapy by assessing blood immune cell activation before and after therapy.

  • NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE

    The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.

  • Methods for Treating Fatty Liver Disease

    The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their sequelae by administration of uridine or a compound that modulates one or more uridine phosphorylases in a subject in need thereof.

  • Methods, Systems, and Computer-Readable Media for Disease Management

    Methods, systems, and computer-readable media provide for disease management. According to embodiments, a method for providing social interaction between a first handheld medical testing and monitoring device and a second handheld medical testing and monitoring device is provided. According to the method, at least one of a social networking profile and a diagnostic profile is received from the first handheld medical testing and monitoring device. A second user associated with the second handheld medical testing and monitoring device is selected based on the at least one of the social networking profile and the diagnostic profile. A user list at the first handheld medical testing and monitoring device is populated with a unique identifier enabling communication between a first user associated with the first handheld medical testing and monitoring device and the second user associated with the second handheld medical testing and monitoring device.

  • System and Implantable Device for Treating Chronic Kidney Disease

    An implantable dialysis device with a related medical system for intracorporeal dialysis and ultrafiltration of blood, and methods of use are described. The medical system includes an extracorporeal module, a cutaneous module, and an implantable module. Features of the implantable module facilitate delivery and flow of blood and dialysate through the medical system. A filter pack within the implantable module performs dialysis and ultrafiltration of blood. System cleansing is also described.

  • SYSTEM AND METHOD FOR MINIMALLY INVASIVE DISEASE THERAPY

    A system for treating a lesion site of a patient is disclosed. The system includes a cannula having a lumen, a conduit in communication with said lumen, an introducer stylet removably disposed within said cannula, a resecting device selectively insertable within said cannula, and an adjuvant treatment device selectively insertable within said cannula.

  • PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE

    Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.

  • COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE

    The present invention provides compositions for reducing amyloid plaque burden associated with Alzheimer's disease and methods of using the same.

  • AQUEOUS SOLUTION COMPRISING 3 - QUINUCLIDINONES FOR THE TREATMENT HYPERPROLIFERATIVE, AUTOIMMUNE AND HEART DISEASE

    A liquid composition that is an aqueous solution of a compound of formula (I), wherein the aqueous solution has a pH from about 3.0 to about 5.0. The liquid composition may be used in the treatment of a disorder selected from hyperproliferative diseases, autoimmune diseases and heart diseases.

  • Agonists of Guanylate Cyclase Useful for the Treatment of Hypercholesterolemia, Atherosclerosis, Coronary Heart Disease, Gallstone, Obesity and Other Cardiovascular Diseases

    This invention also provides a method to prevent, control, and treata lipid metabolism disorder, a biliary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.

  • METHODS AND COMPOSITIONS FOR DIAGNOSIS OR PROGNOSIS OF CARDIOVASCULAR DISEASE

    The invention provides methods of screening a mammalian subject to determine if the subject is at risk to develop or is suffering from, cardiovascular disease. In one embodiment, the method comprises detecting a measurable feature of at least two biomarkers in an EMT subfraction, or in a complex containing apoA-I or apoA-III isolated from a biological sample obtained from the subject, wherein the at least two biomarkers are selected from the group consisting of apoA-I, apoA-II, apoB-100, Lp(a), apoC-I, and apoC-III, combinations or portions and/or derivatives thereof, and comparing the measurable features of the at least two biomarkers from the biological sample to a reference standard, wherein a difference in the measurable features of the at least two biomarkers from the biological sample and the reference standard is indicative of the presence or risk of cardiovascular disease in the subject.

  • ELECTROCHEMICAL METHODS OF DETECTING COLON CANCER CELLS AND USE OF SAME FOR DIAGNOSING AND MONITORING TREATMENT OF THEDISEASE

    A method of detecting cancer cells is disclosed. The method comprises (a) contacting the cell with a substrate for an enzyme under conditions wherein the enzyme catalyzes a reaction of the cell with the substrate, so as to generate a product capable of producing an electrical signal; and (b) measuring a level of the electrical signal, wherein a difference in a level of the electrical signal compared to a predetermined threshold is indicative of a cancer cell. The method may be adapted for diagnosis, monitoring a cancer therapy, identifying agents capable of treating cancer and individually optimizing a cancer therapy.

  • DIFFERENTIAL GENE EXPRESSION FOR DETECTING AND/OR DIFFERENTIATING LUNG DISEASE

    Disclosed herein are methods, constructs, kits, and the like, which can be used for detecting and/or differentiating interstitial lung disease. For example, idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP) can be detected and/or differentiated using at least one biomarker.

  • TREATMENT OF HEART DISEASE

    Disclosed herein are methods, compositions and kits for treating cardiac stem cells to be administered to a subject in need thereof, e.g., with a damaged myocardium. The methods, composition and kits of the invention can be used to treat cardiovascular diseases such as heart failure, myocardial infarction and an age-related cardiomyopathy.

  • PEPTIDE WHICH PASSES THROUGH BLOOD-BRAIN BARRIER AND TARGETS APOPTOSIS OF NEURODEGENERATIVE BRAIN DISEASE SITE AND USES THEREOF

    The present invention relates to a peptide that passes through a blood-brain barrier and targets apoptosis of neurodegenerative brain disease-affected sites and uses thereof. More particularly, the present invention relates to a composition for delivering drugs to brain tissues, a composition for detecting apoptotic cells of neurodegenerative brain disease-affected sites, and a composition for imaging the neurodegenerative brain disease-affected sites which comprises a peptide having an amino acid sequence represented by SEQ ID: No. 1 respectively, and a composition for prevention, treatment, or theranosis of neurodegenerative brain diseases comprising said peptide. The peptide of the present invention can be used for detecting apoptosis in neurodegenerative brain diseases and further detecting apoptotic cells (especially apoptotic neuronal cells) in neurodegenerative brain disease-affected sites and imaging, targeted drug delivery, theranosis.

  • GLOBAL DISEASE SURVEILLANCE PLATFORM, AND CORRESPONDING SYSTEM AND METHOD

    A computer-implemented method for identifying and assessing public health events, and a corresponding system and apparatus, includes capturing public health-related information from structured and unstructured sources, where the information is contained in one or more documents, extracting meta-data from the captured public health-related information, creating an index of the extracted meta-data; archiving the meta-data and the documents, where the index links meta-data to its associated document, processing the extracted meta-data according to one or more detection algorithms to determine if an anomaly exists, and where an anomaly exists, providing a public health event notification, and monitoring and evaluating the responses to the public health events.

  • GLOBAL DISEASE SURVEILLANCE PLATFORM, AND CORRESPONDING SYSTEM AND METHOD

    A computer-implemented method for identifying and assessing public health events, and a corresponding system and apparatus, includes capturing public health-related information from structured and unstructured sources, where the information is contained in one or more documents, extracting meta-data from the captured public health-related information, creating an index of the extracted meta-data; archiving the meta-data and the documents, where the index links meta-data to its associated document, processing the extracted meta-data according to one or more detection algorithms to determine if an anomaly exists, and where an anomaly exists, providing a public health event notification, and monitoring and evaluating the responses to the public health events.

  • TREATMENT OF HYPERTENSION AND HEART DISEASE VIA SURGERY OF THE STOMACH

    Devices and methods for endolumenally manipulating stomach fundus tissue alter the function of nearby nerves. The altered function of the nerves interacts with the cardiopulmonary system to cause a substantially permanent reduction in blood pressure. The altered nerve function may also treat heart disease as well. This application also relates to devices and methods for endolumenally manipulating stomach tissue to alter hormone production from cells associated with stomach tissue, providing a therapeutic effect in treating hypertension and heart disease, not conventionally associated with the stomach.

  • Determination of a Measure of a Glycation End-Product or Disease State Using Tissue Fluorescence Lifetime

    The present invention provides methods and apparatuses for determining a measure of a tissue state in an individual. Light emitted by tissue of the individual due to fluorescence of a chemical with the tissue detected. The invention can comprise measuring the fluorescence lifetime in either time-domain or frequency domain modes. The invention can also comprise a variety of models relating fluorescence to a measure of tissue state, for example, multivariate models can be developed that relate lifetime trends of one or more constituents to increasing propensity to diabetes and pre-diabetes. Other biologic information can be used in combination with the fluorescence properties to aid in the determination of a measure of tissue state.

  • USE OF PERLECAN DOMAIN V IN TREATING AMYLOIDOGENIC DISEASE

    The application reports that perlecan domain V (DV) or the LG3 domain thereof reduces deposition and toxicity of A.beta. peptide, the major component of plaques in Alzheimer's disease. Methods of using DV, LG3 and related molecules in treatment of amyloidogenic diseases, particularly Alzheimer's disease, are provided.

  • METHOD FOR ASSESSMENT OF POTENTIAL FOR DEVELOPMENT OF DRAVET SYNDROME AND USE THEREOF

    Provided is a method of assessing a potential for development of Dravet syndrome with high accuracy, and use thereof. The method according to the present invention of assessing a potential for development of Dravet syndrome includes, with use of a sample taken from a subject, detecting whether or not a mutation is on .alpha.-subunit type 1 of voltage-gated sodium ion channel Na.sub.V1.1, and detecting whether or not a mutation is on .alpha.-subunit type 1 of voltage-gated calcium ion channel Ca.sub.V2.1.

  • ANTISENSE OLIGONUCLEOTIDES THAT TARGET A CRYPTIC SPLICE SITE IN USH1C AS A THERAPEUTIC FOR USHER SYNDROME

    The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length within exon 3 of an Usher RNA transcript.

  • COMPOSITIONS AND METHODS FOR DETECTING NOONAN SYNDROME

    Diagnostic and therapeutic applications for Noonan Syndrome are described. The diagnostic and therapeutic applications are based on certain mutations in a RAS-specific guanine nucleotide exchange factor gene SOS1 or its expression product. The diagnostic and therapeutic applications are also based on certain mutations in a serine/threonine protein kinase gen RAF1 or its expression product thereof. Also described are nucleotide sequences, amino acid sequences, probes, and primers related to RAF1 or SOS1, and variants thereof, as well as host cells expressing such variants.

  • NOVEL GENOMIC BIOMARKERS FOR IRRITABLE BOWEL SYNDROME DIAGNOSIS

    The invention provides novel biomarkers, kits, and methods of diagnosing, prognosing, and subtyping IBS. In one aspect, the invention provides novel genomic biomarkers for diagnosing, classifying, providing a prognosis for, and assigning therapy for IBS in a subject in need thereof. In another aspect, the present invention provides novel algorithms for the diagnosis and prognosis of IBS.

  • DIETARY SUPPLEMENT FOR USE IN A WEIGHT LOSS PROGRAM

    This invention relates to a dietary supplement for use in a weight loss program, which alleviates insulin resistance in the presence of the metabolic syndrome. The dietary supplement includes, in combination, berberine, banaba leaf extract, and inositol. Also provided is a method of treatment in a weight loss program.

  • PHARMACEUTICAL FOR PREVENTING OR TREATING AN INNER EAR DISORDER

    A pharmaceutical for preventing or treating an inner ear disorder, comprising a spirohydantoin derivative represented by a general formula (I): ##STR00001## in the formula, X represents a halogen atom or a hydrogen atom, and R.sup.1 and R.sup.2 simultaneously or individually represent a hydrogen atom or an optionally substituted C.sub.1-6 alkyl group, or a pharmacologically acceptable salt thereof as an active ingredient.

  • METHOD FOR EXAMINING ACUTE RENAL DISORDER

    Provided is a test method for acute kidney injury, including detecting urinary podocalyxin. According to the test method, a subject to be tested who has a higher value for the urinary podocalyxin than a reference value can be assessed to have acute kidney injury. Further, as compared to a conventional method, the test method allows acute kidney injury to be assessed accurately and non-invasively, which allows a physical burden on a patient to be reduced. Thus, the test method is useful.

  • METHOD AND APPARATUS FOR DETERMINING POTENTIAL MOVEMENT DISORDER USING SENSOR DATA

    An approach is provided for determining potential movement disorder using sensor data. The health and wellness engine processes and/or facilitates a processing of one or more sequences of images to identify one or more reference objects, the one or more sequences of images captured via a device physically attached to a user. The health and wellness engine determines movement information of the one or more reference objects within the one or more sequences of images, wherein the movement information is at least substantially attributable to one or more physical movements of the user. The health and wellness engine processes and/or facilitates a processing of the movement information to cause, at least in part, a determination of one or more potential movement disorders associated with the user.

  • Method for the Treatment, Alleviation of Symptoms of, Relieving, Improving and Preventing a Cognitive Disease, Disorder or Condition

    The present invention provides uses of a salt adduct comprising at least one positively charged moiety being a pyridoxine or a derivative thereof and at least one carboxylated 5- to 7-membered lactam ring, optionally additionally substituted, for the preparation of a medicament for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition in a subject. Additionally, the invention provides use of said salt adducts for the preparation of medicaments for the improvement of cognitive functions in a healthy subject.

  • DISEASE RISK DECISION SUPPORT PLATFORM

    A system provides a disease specific risk reference and includes a plurality of executable item modules that each define a different elementary disease to family structure relationship for a specific disease represented as a logical Boolean operation, and an item scoring engine that ranks positively scored item modules based on a risk level associated with a corresponding elementary disease to family structure relationship, wherein the positive scores identify an existence of a given disease to family structure relationship. The system further includes a disease specific risk reference generator that extracts item content associated with a subset of the highest ranked positively scored item modules from memory and provides the extracted item content in a disease specific risk reference for review by a clinician.

  • Selection of Preferred Sample Handling and Processing Protocol for Identification of Disease Biomarkers and Sample Quality Assessment

    The subject invention relates to methods for obtaining biological samples of improved quality. It encompasses the identification of markers or proteins in biological samples that are altered due to variations in sample collection, handling and processing. They are also useful for correcting variations in measured results for disease biomarkers. Further, they can permit the rejection of samples or groups of samples as necessary if it is determined that their collection method was not in accordance with the predetermined protocol. Other advantages useful to the skilled artisan are described herein.

  • Model Based Control of Parkinson's Disease

    The present invention relates to a novel means to use a fundamental model of the parts of the brain that are dysfunctional in Parkinson's disease, and related dynamical diseases of the brain, as part of a feedback control system to modulate the signs and symptoms of disease. Fundamental computational models that embody our knowledge of the anatomy, neurons, and dynamics of the parts of the brain we wish to control, and use those models to reconstruct what is inaccessible to our measurements. Through emulation the controller synchronizes to the parts of the brain we wish to observe and track. By passing simultaneous control pulses to both the model controller, as well as the brain, we control both the model and the brain. The detailed framework to embed fundamental models of the brain within a control scheme to control symptoms of Parkinsons and related dynamical diseases of the brain are disclosed.

  • METHODS FOR ASSESSING RISK OF ALZHEIMER'S DISEASE IN A PATIENT

    Disclosed are methods for diagnosis or prognosis of Alzheimer's disease in a patient. The methods may include assessing whether a patient has Alzheimer's disease or assessing a patient's risk for developing Alzheimer's disease. The methods typically include determining, either directly or indirectly, whether the patient has mutations, such as single nucleotide polymorphisms, in a plurality of genes that encode gene products that function in steroid biosynthesis.

  • COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CORONARY HEART DISEASE

    The invention pertains to a method of determining a statin dosage for an individual in need of treatment with a statin, comprising determining a SLCO1B1 genotype from a nucleic acid sample of the individual, said genotype comprising the presence or absence of the SLCO1B1-056 polymorphism, and determining an ApoE genotype or phenotype identifying an ApoE polymorphism selected from the group consisting of ApoE2, ApoE3, ApoE4, and any combination thereof, wherein the combination of a SLCO1B1 genotype identifying the presence of the SLCO1B1-056 C polymorphism and the ApoE genotype or phenotype identifying one of the ApoE3/4 or ApoE4/4 genotypes indicates the statin dosage.

  • PEPTOIDS AND METHODS FOR TREATING ALZHEIMER'S DISEASE

    Provided herein are peptoids capable of inhibiting or reversing amyloid .beta. (A.beta.) fibril or plaque production. The peptoids form a helical structure with three monomers per helical turn and have at least two monomers with a side-chain having an arylalkyl group having the same chirality positioned such that the side-chains are on the same side of the peptoid. Also provided are methods of using the peptoids to inhibit or reverse aggregation of A.beta. and methods of treating subjects with Alzheimer's disease (AD) or slowing the progression of AD.

  • METHOD OF TREATING ALZHEIMER'S DISEASE USING PHARMACOLOGICAL CHAPERONES TO INCREASE PRESENILIN FUNCTION AND GAMMA-SECRETASE ACTIVITY

    The present invention relates to a method for treating an individual having Alzheimer's Disease by using pharmacological chaperones that bind presenelin and thereby increase .gamma.-secretase activity.

  • METHOD FOR DIAGNOSING KIDNEY DISEASE COMPRISING DETECTING THE LEVEL OF ANNEXIN A2 OR S100A6

    The present invention provides biomarkers for detecting kidney disease, selected from the oligonucleotide sequence, complementary sequence or derivatives, amino acid sequence or derivatives, fragment, variants, antibody of annexin A2 or S100A6 or combinations thereof. Moreover, the present invention also provides an assay kit and a method for kidney disease detecting, practically for the kidney disease resulting from acute tubular necrosis.

  • RECOMBINANT NON-PATHOGENIC MAREK'S DISEASE VIRUS CONSTRUCTS ENCODING INFECTIOUS LARYNGOTRACHEITIS VIRUS AND NEWCASTLEDISEASE VIRUS ANTIGENS

    The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines.

  • METHODS FOR PREVENTING OR TREATING A DISEASE OR CONDITION ASSOCIATED WITH MYCOBACTERIUM AVIUM SUBSPECIES

    This invention is a method for immunizing, preventing or treating a Mycobacterium avium subspecies paratuberculosis-associated disease or condition by screening subjects for markers indicative of predisposition or susceptibility to a Mycobacterium avium subspecies paratuberculosis-associated disease or condition and administering a Mycobacterium avium subspecies paratuberculosis vaccine or prophylactic or therapeutic agent.

  • Use Of Tight Junction Antagonists To Treat Inflammatory Bowel Disease

    The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents.

  • COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS

    The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

  • METHODS FOR TREATING NEUROLOGICAL DISEASE

    Neurological disorders and diseases, such as Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and Down's syndrome, can be ameliorated or beneficially treated by administration of a formulation comprising an effective amount of a pyrone-indole derivative of formula (I) Ar--B--Ar' (I) wherein AR represents an indole nucleus ring system: ##STR00001## Ar' represents an alpha-, beta- or gamma-pyrone nucleus ring system: ##STR00002## and each of B, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.1' and R.sub.2' are as defined herein.

  • COMPOSITIONS AND METHODS FOR TREATING CARDIVASCULAR DISEASE

    The invention pertains to methods of treating cardiovascular disease by modulating inflammatory and immunoregulatory responses associated with such pathological conditions. Embodiments of the invention provide methods for the treatment of cardiovascular disease comprising administering an effective amount of one or more IL-17 antagonists, IL-18 antagonists, 4-1BB antagonists, CD30 antagonists, OX40 antagonists and/or CD39 alone or in any combination.

  • METHODS OF TREATING CELIAC DISEASE

    Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of celiac disease or a related disorder. Also described herein is a method for treating a subject with celiac disease or a related disorder using digestive enzymes and their derivatives to alleviate the symptoms of celiac disease or a related disorder. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of celiac disease or a related disorder.

  • Methods for Diagnosis of Cardiovascular Disease

    This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.

  • HETEROCYCLIC PYRIMIDINE CARBONIC ACID DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRALDISEASE

    The present invention relates to a compound having the general formula (C), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, ##STR00001## which are useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

  • D-AMINO ACID COMPOUNDS FOR LIVER DISEASE

    Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

  • COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS

    The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

  • METHODS FOR TREATING NEUROLOGICAL DISEASE

    Neurological disorders and diseases, such as Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and Down's syndrome, can be ameliorated or beneficially treated by administration of a formulation comprising an effective amount of a pyrone-indole derivative of formula (I) Ar--B--Ar' (I) wherein AR represents an indole nucleus ring system: ##STR00001## Ar' represents an alpha-, beta- or gamma-pyrone nucleus ring system: ##STR00002## and each of B, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.1' and R.sub.2' are as defined herein.

  • COMPOSITIONS AND METHODS FOR TREATING CARDIVASCULAR DISEASE

    The invention pertains to methods of treating cardiovascular disease by modulating inflammatory and immunoregulatory responses associated with such pathological conditions. Embodiments of the invention provide methods for the treatment of cardiovascular disease comprising administering an effective amount of one or more IL-17 antagonists, IL-18 antagonists, 4-1BB antagonists, CD30 antagonists, OX40 antagonists and/or CD39 alone or in any combination.

  • METHODS OF TREATING CELIAC DISEASE

    Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of celiac disease or a related disorder. Also described herein is a method for treating a subject with celiac disease or a related disorder using digestive enzymes and their derivatives to alleviate the symptoms of celiac disease or a related disorder. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of celiac disease or a related disorder.

  • Methods for Diagnosis of Cardiovascular Disease

    This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.

  • HETEROCYCLIC PYRIMIDINE CARBONIC ACID DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRALDISEASE

    The present invention relates to a compound having the general formula (C), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, ##STR00001## which are useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

  • HETEROCYCLIC PYRIMIDINE CARBONIC ACID DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRALDISEASE

    The present invention relates to a compound having the general formula (C), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, ##STR00001## which are useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

  • D-AMINO ACID COMPOUNDS FOR LIVER DISEASE

    Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

  • METHOD OF TREATING OF GASTROESOPHAGEAL REFLUX DISEASE

    The development of agents for gastroesophageal reflux disease, in which existing treatment is not effective, is strongly demanded. An object of the present invention is to provide an agent for preventing or relapse-preventing, treating or ameliorating such gastroesophageal reflux disease. 4-[({6-[Isobutyl(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1H-- inden-5-yl}oxy)methyl]-3-methyl benzoic acid, a salt thereof or a prodrug thereof is effective in the prevention or relapse prevention, treatment or amelioration of gastroesophageal reflux disease.

  • METHOD OF TREATING OF GASTROESOPHAGEAL REFLUX DISEASE

    A method for treatment of chronic obstructive pulmonary disease includes occluding at least one of a bronchial tube and emphysema, and deciding whether or not a bypass has been formed by the occlusion.

  • LaFORA'S DISEASE GENE

    A novel gene (EPM2A) that is deleted or mutated in people with Lafora's disease is described. The EPM2A gene encodes a protein having an active catalytic site of a protein tyrosine phosphatase. Many different sequence mutations as well as several microdeletions in EPM2A have been found that co-segregate with Lafora's disease.

  • Methods for Detecting an increased risk for coronary heart disease

    The invention relates generally to an allele on human chromosome 9 associated with increased risk for coronary heart disease and the use or detection of such an allele in determining whether a human has an increased risk for coronary heart disease. In one aspect, the invention relates to methods for detecting a predisposition or propensity or susceptibility for coronary heart disease in a human, comprising detecting the presence of an allele on human chromosome 9 that is associated with an increased risk for coronary heart disease in a human. Disclosed are methods and compositions for determining whether a person carries an allele associated with increased risk for coronary atherosclerosis by determining whether the person has an RA-CHR9 allele, such as by determining whether the person has an RA-CHR9 allele-associated single nucleotide polymorphism (SNP). The invention also relates to kits for detecting the presence of an allele on chromosome 9 associated with an increased risk for coronary heart disease.

  • METHODS FOR THERAPY OF NEURODEGENERATIVE DISEASE OF THE BRAIN

    A specific clinical protocol for use toward therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Parkinson's disease and Alzheimer's disease. The protocol is practiced by delivering a definite concentration of recombinant neurotrophin, such as glial cell-derived neurotrophic factor), into a targeted region of the brain (such as the substantia nigra) using a lentiviral expression vector. The neurotrophin is delivered to, or within close proximity of, identified defective, diseased or damaged brain cells. The concentration of neurotrophin delivered as part of a neurotrophic composition varies from 10.sup.10 to 10.sup.15 neurotrophin encoding viral particles/ml of composition fluid. Each delivery site receives from 2.5 .mu.l to 25 .mu.l of neurotrophic composition, delivered slowly, as in over a period of time ranging upwards of 10 minutes/delivery site. Each delivery site is at, or within 500 .mu.m of, a targeted cell, and no more than about 10 mm from another delivery site. The method stimulates growth of targeted neurons, and reversal of functional deficits associated with the neurodegenerative disease being treated.

  • OPIOIDS FOR THE TREATMENT OF THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    The present invention relates to an opioid controlled release oral dosage form comprising at least one opioid for the manufacture of a medicament to treat patients with Chronic Obstructive Pulmonary Disease (COPD).

  • TREATMENT OF CROHN'S DISEASE WITH LAQUINIMOD

    This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease.